Maze Therapeutics (MAZE) Earnings Date & Reports

Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

MAZE is expected to report earnings to fall 25.00% to -56 cents per share on November 05

Maze Therapeutics MAZE Stock Earnings Reports

Q3'26

Est.

$-0.57

Q2'26

Missed

by $0.19

Q1'26

Beat

by $0.13

Q4'25

Missed

by $0.02

Q3'25

Missed

by $0.04

The last earnings report on August 11 showed earnings per share of -75 cents, missing the estimate of -56 cents. With 994.24K shares outstanding, the current market capitalization sits at 1.58B.

View a ticker or compare two or three

MAZE

Daily Signal:

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

View AI-Driven Trading for MAZE